Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer’s disease — a target for neuroprotective treatment strategies?

  • G. Münch
  • W. Deuther-Conrad
  • J. Gasic-Milenkovic
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 62)


Accumulation of Advanced Glycation Endproducts (AGEs) in the brain is a feature of ageing and degeneration, especially in Alzheimer’s disease (AD). Increased AGE levels explain many of the neuropathological and biochemical features of AD such as extensive protein crosslinking (β-amyloid and MAP-tau), glial activation, oxidative stress and neuronal cell death. Oxidative stress and AGEs initiate a positive feedback loop, where normal age-related changes develop into a pathophysiological cascade. Combined intervention using antioxidants, anti-inflammatory drugs and AGE-inhibitors may be a promising neuroprotective strategy.


Vicious Cycle Lipoic Acid Advanced Glycation Endproducts Thioctic Acid High Molecular Weight Hyaluronic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bruce-Keller AJ, Li YJ, Lovell MA, Kraemer PJ, Gary DS, Brown RR, Markesbery WR, Mattson MP,(1998) 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats. J Neuropathol Exp Neuro l57: 257–267Google Scholar
  2. Gsell W, Conrad R, Hickethier M, Sofic E, Frolich L, Wichart I, Jellinger K, Moll G, Ransmayr G, Beckmann H, Riederer P (1995) Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64: 1216–1223PubMedCrossRefGoogle Scholar
  3. Hager K, Marahrens A, Kenklies M, Riederer P, Munch G,(2001) Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatr 32: 275–282PubMedCrossRefGoogle Scholar
  4. Ihl R, Perisic I, Maurer K, Dierks T, (1989) Effect of 3 months treatment with tenilsetam in patients suffering from dementia of Alzheimer type (DAT). J Neural Transm [P-D Sect] 1: 84–85CrossRefGoogle Scholar
  5. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT, (1997) App(SW) transgenic mice develop age-related A-beta deposits and neuropil abnormalities, but no neuronal loss in CA 1. J Neuropathol Exp Neurol 56: 965–973PubMedCrossRefGoogle Scholar
  6. Loske C, Gerdemann A, Schepl W, Wycislo M, Schinzel R, Palm D, Riederer P, Munch G, (2000) Transition metal mediated glycoxidation accelerates crosslinking of (3-amyloid peptide. Eur J Biochem 267: 4171–4178PubMedCrossRefGoogle Scholar
  7. Munch G, Taneli Y, Schraven E, Schindler U, Schinzel R, Palm D, Riederer P, (1994) The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J Neural Transm [P-D Sect] 8:193–208CrossRefGoogle Scholar
  8. Munch G, Mayer S, Michaelis J, Hipkiss AR, Riederer P, Miiller R, Neumann A., Schinzel R, Cunningham A.M, (1997) Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim Biophys Acta 1360:17–29PubMedCrossRefGoogle Scholar
  9. Neumann A, Schinzel R, Palm D, Riederer P, Munch G, (1999) High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappa B activation and cytokine expression. FEBS Lett 453: 283–287Google Scholar
  10. Retz W, Gsell W, Munch G, Rosier M, Riederer P, (1998) Free radicals in Alzheimer’s disease. J Neural Transm [Suppl 54]: 221–236Google Scholar
  11. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, et al (1993) Clinical trial of indomethacin in Alzheimer’s disease. Neurology 43: 1609–1611PubMedCrossRefGoogle Scholar
  12. Schweers O, Mandelkow EM, Biernat J, Mandelkow E, (1995) Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc Natl Acad Sci USA 92: 8463–8467PubMedCrossRefGoogle Scholar
  13. Smith MA, Sayre LM, Monnier VM, Perry G, (1996) Oxidative posttranslational modifications in Alzheimer disease ¡ª a possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Mol Chem Neuropathol 28: 41–48PubMedCrossRefGoogle Scholar
  14. Stadelmann C, Bruck W, Bancher C, Jellinger K, Lassmann H, (1998) Alzheimer-disease ¡ª DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. Neuropathol Exp Neurol 57: 456–464CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • G. Münch
    • 1
  • W. Deuther-Conrad
    • 1
  • J. Gasic-Milenkovic
    • 1
  1. 1.Neuroimmunological Cell BiologyInterdisciplinary Center of Clinical Research (IZKF)LeipzigFederal Republic of Germany

Personalised recommendations